Published in J Clin Sleep Med on August 15, 2010
Resistant hypertension and obstructive sleep apnea in the setting of kidney disease. J Hypertens (2012) 1.49
Role of obstructive sleep apnea in cardiovascular disease. Curr Opin Cardiol (2011) 1.12
Pathogenesis of obstructive sleep apnoea in hypertensive patients: role of fluid retention and nocturnal rostral fluid shift. J Hum Hypertens (2014) 1.04
A randomized, double crossover study to investigate the influence of saline infusion on sleep apnea severity in men. Sleep (2014) 1.01
Association of severe obstructive sleep apnea and elevated blood pressure despite antihypertensive medication use. J Clin Sleep Med (2014) 1.00
Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens (2011) 0.98
Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes. J Hum Hypertens (2013) 0.93
Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension. Hypertension (2016) 0.90
Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens (2011) 0.89
Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag (2013) 0.88
Hypertension and obstructive sleep apnea. Hypertens Res (2016) 0.88
Obstructive sleep apnea, hypertension and cardiovascular diseases. J Hum Hypertens (2015) 0.87
Treatment of primary aldosteronism is associated with a reduction in the severity of obstructive sleep apnoea. J Hum Hypertens (2017) 0.85
Effects of continuous positive airway pressure on blood pressure in patients with resistant hypertension and obstructive sleep apnea: a meta-analysis. J Hypertens (2014) 0.84
Angiotensin II type 1a receptors in subfornical organ contribute towards chronic intermittent hypoxia-associated sustained increase in mean arterial pressure. Am J Physiol Heart Circ Physiol (2014) 0.82
Resistant hypertension and obstructive sleep apnea. Int J Hypertens (2013) 0.79
Relationship between aldosterone and the metabolic syndrome in patients with obstructive sleep apnea hypopnea syndrome: effect of continuous positive airway pressure treatment. PLoS One (2014) 0.78
Resistant hypertension-complex mix of secondary causes and comorbidities. J Hum Hypertens (2013) 0.75
Longitudinal Effect of CPAP on BP in Resistant and Nonresistant Hypertension in a Large Clinic-Based Cohort. Chest (2016) 0.75
Effect of Antihypertensive Medications on the Severity of Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis. J Clin Sleep Med (2016) 0.75
Resistant hypertension and untreated severe sleep apnea: slowly gaining insight. J Clin Sleep Med (2014) 0.75
Meta-analysis of effects of obstructive sleep apnea on the renin-angiotensin-aldosterone system. J Geriatr Cardiol (2016) 0.75
Distinctive Risk Factors and Phenotype of Younger Patients With Resistant Hypertension: Age Is Relevant. Hypertension (2017) 0.75
The Triad of Sleep Apnea, Hypertension, and Chronic Kidney Disease: A Spectrum of Common Pathology. Cardiorenal Med (2016) 0.75
Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines! Front Cardiovasc Med (2015) 0.75
Association of aldosterone excess and apnea-hypopnea index in patients with resistant hypertension. Sci Rep (2017) 0.75
Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen & Kales (1968) standard. Psychiatry Clin Neurosci (2001) 36.50
Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med (2000) 18.12
Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet (2005) 17.31
Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med (2005) 13.14
Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med (2001) 12.29
Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep (2008) 8.69
Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension (2008) 6.96
Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2008) 6.48
Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA (2003) 5.39
Identification of upper airway anatomic risk factors for obstructive sleep apnea with volumetric magnetic resonance imaging. Am J Respir Crit Care Med (2003) 4.14
High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens (2001) 2.95
Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension (2002) 2.46
Contrasting effects of hypoxia and hypercapnia on ventilation and sympathetic activity in humans. J Appl Physiol (1985) (1989) 2.04
Influence of ventilation and hypocapnia on sympathetic nerve responses to hypoxia in normal humans. J Appl Physiol (1985) (1989) 1.91
Sleep apnoea in a hypertensive population. Lancet (1984) 1.90
Adult obstructive sleep apnea: pathophysiology and diagnosis. Chest (2007) 1.86
Prevalence of sleep apnea syndrome among patients with essential hypertension. Am Heart J (1984) 1.83
Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens (2004) 1.75
Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol (2006) 1.72
Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med (2008) 1.68
Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest (2007) 1.65
Alterations in upper airway cross-sectional area in response to lower body positive pressure in healthy subjects. Thorax (2007) 1.60
Day-night variation of acute myocardial infarction in obstructive sleep apnea. J Am Coll Cardiol (2008) 1.50
Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats. Am J Physiol Heart Circ Physiol (2007) 1.46
Sleep apnea syndrome and essential hypertension. Am J Cardiol (1985) 1.43
Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens (2003) 1.35
Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis (2001) 1.31
Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens (2003) 1.24
Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension (2002) 1.23
Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest (2004) 1.21
Diuretics in obstructive sleep apnea with diastolic heart failure. Chest (2007) 1.12
Leptin and the ventilatory response to exercise in heart failure. J Am Coll Cardiol (2003) 0.88
Interaction between the angiotensin-converting enzyme gene insertion/deletion polymorphism and obstructive sleep apnoea as a mechanism for hypertension. J Hypertens (2007) 0.85
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med (2006) 9.40
Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension (2008) 6.96
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. Circulation (2011) 5.26
Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation (2008) 5.26
The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension (2011) 5.14
Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension (2009) 4.26
Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation (2007) 4.16
A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum (2012) 4.01
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med (2003) 3.78
Evidence-based guidelines for cardiovascular disease prevention in women. Circulation (2004) 3.39
Pathogenesis of hypertension. Ann Intern Med (2003) 3.18
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 2.96
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. J Am Coll Cardiol (2011) 2.89
Blood pressure measurement device, number and timing of visits, and intra-individual visit-to-visit variability of blood pressure. J Clin Hypertens (Greenwich) (2012) 2.85
Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension (2013) 2.83
Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension (2013) 2.74
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension (2005) 2.69
Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Clin Hypertens (Greenwich) (2013) 2.64
Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens (2003) 2.54
Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol (2003) 2.47
Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. Ann Intern Med (2015) 2.42
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2012) 2.42
Magnetic resonance imaging with 3-dimensional analysis of left ventricular remodeling in isolated mitral regurgitation: implications beyond dimensions. Circulation (2012) 2.37
Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ Res (2007) 2.32
Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med (2005) 2.26
Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) (2011) 2.11
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann Intern Med (2003) 2.09
Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol (2013) 2.08
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med (2009) 2.02
Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol (2009) 2.01
An argument for reviving the disappearing skill of cardiac auscultation. Cleve Clin J Med (2012) 2.00
Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov (2002) 1.98
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation (2011) 1.97
Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. Chest (2013) 1.88
Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension (2010) 1.85
Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension (2009) 1.82
Estrogen modulates TNF-alpha-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-beta activation. Am J Physiol Heart Circ Physiol (2007) 1.80
Genome-wide detection of LOH in prostate cancer using human SNP microarray technology. Genomics (2003) 1.80
Sex hormones and hypertension. Cardiovasc Res (2002) 1.74
Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure. Circulation (2010) 1.73
Trends in hypertension prevalence, awareness, treatment, and control among US adults 80 years and older, 1988-2010. J Clin Hypertens (Greenwich) (2014) 1.72
Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J Am Coll Cardiol (2007) 1.69
Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med (2008) 1.68
Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol (2012) 1.66
Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest (2007) 1.65
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clin J Am Soc Nephrol (2012) 1.62
Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse. Hypertension (2003) 1.61
Oral corticosteroids increase esophageal acid contact times in patients with stable asthma. Chest (2002) 1.61
Relation of torsion and myocardial strains to LV ejection fraction in hypertension. JACC Cardiovasc Imaging (2012) 1.61
Evidence-based guidelines for cardiovascular disease prevention in women. J Am Coll Cardiol (2004) 1.59
Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcomes (2012) 1.59
Aldosterone excess and resistance to 24-h blood pressure control. J Hypertens (2007) 1.54
Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system. Am J Physiol Heart Circ Physiol (2008) 1.53
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens (2004) 1.53
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension (2004) 1.52
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation (2011) 1.52
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens (2002) 1.51
Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail (2010) 1.50
Moderate waist circumference and hypertension prevalence: the REGARDS Study. Am J Hypertens (2011) 1.50
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. Hypertension (2005) 1.49
Evidence-based guidelines for cardiovascular disease prevention in women. American Heart Association scientific statement. Arterioscler Thromb Vasc Biol (2004) 1.49
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens (2009) 1.48
Phosphatidylinositol-3-kinase signaling mediates vascular smooth muscle cell expression of periostin in vivo and in vitro. Atherosclerosis (2005) 1.48
Resistant hypertension: incidence, prevalence, and prognosis. Circulation (2012) 1.46
Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension (2008) 1.46
Transforming growth factor-beta signaling mediates hypoxia-induced pulmonary arterial remodeling and inhibition of alveolar development in newborn mouse lung. Am J Physiol Lung Cell Mol Physiol (2008) 1.45
Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Soc Hypertens (2015) 1.45
Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension (2008) 1.44
Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status. J Hypertens (2016) 1.43
Salt sensitivity, a determinant of blood pressure, cardiovascular disease and survival. J Am Coll Nutr (2006) 1.41
Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc (2013) 1.31
Hypoxia-responsive growth factors upregulate periostin and osteopontin expression via distinct signaling pathways in rat pulmonary arterial smooth muscle cells. J Appl Physiol (1985) (2004) 1.31